-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Efficacy and safety of the #SGLT2 inhibitor #empagliflozin vs placebo and the #DPP-4 inhibitor #linagliptin versus placebo in young people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
New—Efficacy and safety of the #SGLT2 inhibitor #empagliflozin versus placebo and the #DPP-4 inhibitor #linagliptin versus placebo in young people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO1cyU #T2D
-
-
Mashup Score: 1
Lifestyle interventions can delay the onset of type 2 diabetes in people with impaired glucose tolerance, but whether this leads subsequently to fewer complications or to increased longevity is uncertain. We aimed to assess the long-term effects of lifestyle …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet-
Impact of #Lifestyle in people with impaired glucose tolerance: 30-year results of the #DaQing study. Similar results in #DPP (Diabetes Prevention Project). Often underestimated by #MD https://t.co/PtsovnBRgN
-
-
Mashup Score: 1
The Diabetes Prevention Program, developed by the Centers for Disease Control and…
Source: Houston ChronicleCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
96 million Americans have #prediabetes. Learn how @first_mile_care, a spinout of @Health2047, our Silicon-Valley based #innovation subsidiary, has helped participants through the CDC's #Diabetes Prevention Program (#DPP). Full story via @HoustonChron: https://t.co/wmyvRDJ1Nv
-
-
Mashup Score: 3IAM1106- Innovator Establishes Best Practices in Preventing Chronic Illnesses - I AM CEO Podcast - 3 year(s) ago
Karl Ronn spent nearly 30 years with Procter & Gamble, winding up as vice president of R&D and general manager of new business/healthcare, where he was responsible for developing P&G’s capability to deliver disruptive innovations. Karl developed new markets for household-name cleaning products like Febreze, Swiffer and Mr. Clean Magic Eraser, as well as personal …
Source: I AM CEO PodcastCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Over 88 million American adults have #prediabetes. Learn more about the CDC-recognized lifestyle change program, the #diabetes prevention program (#DPP), from @kpronn, founder & CEO of @first_mile_care, on the @iamceopod. #IAMCEO https://t.co/BqDDUfpjiy
-
-
Mashup Score: 0
In this large, international, observational study, initiation of SGLT2 inhibitors versus DPP-4 inhibitors was associated with lower risks of heart failure, death, myocardial infarction, and stroke, providing further support for the cardiovascular benefits associated with use of SGLT2 inhibitors in patients with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Research Article: Risk of #cardiovascular events and death associated with initiation of #SGLT2 inhibitors compared with #DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study https://t.co/387b2KofCb
-
-
Mashup Score: 7
In this large, international, observational study, initiation of SGLT2 inhibitors versus DPP-4 inhibitors was associated with lower risks of heart failure, death, myocardial infarction, and stroke, providing further support for the cardiovascular benefits associated with use of SGLT2 inhibitors in patients with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Research Article: Risk of #cardiovascular events and death associated with initiation of #SGLT2 inhibitors compared with #DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study https://t.co/387b2KofCb
-
-
Mashup Score: 2Health in 2 Point 00, Episode 139 | More Funding Deals & Livongo’s Diabetes Prevention Program - 4 year(s) ago
Health tech deals are just back to back this week! On Episode 139 of Health In 2 Point 00, Jess asks me about Withings getting $60M in a new round to develop their connected devices & apps products, Neurovalens raising €5.5M to grow their headset technology that helps with obesity, insomnia, diabetes, & more, Pocket…
Source: The Health Care BlogCategories: General Medicine News, Latest HeadlinesTweet-
On Ep. 139 of #Healthin2Point00, @jessdamassa asks @boltyboy about @WithingsEN raising $60M, @Neurovalens raising €5.5M, @MyPocketHealth raising $6.5M, and @sidecar_health raising $20M. They also talk about @Livongo's new #DPP program on @THCBstaff https://t.co/fbx7sLvywx
-
-
Mashup Score: 0DPP Continues to Yield Positive Results, New DPPOS Data Show - 4 year(s) ago
New results from the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association’s 80th Scientific Sessions, showed persistent reductions in type 2 diabetes (T2D) development over an average 22-year follow-up period.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#DPP Continues to Yield Positive Results, New #DPPOS Data Show: https://t.co/ApfRq3X6eB #ADA2020 #ADAGoesVirtual https://t.co/7HvgKt59SX
-
Online—Efficacy & safety of the #SGLT2 inhibitor #empagliflozin vs placebo & the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D